Joyce M van Dodewaard-de Jong1,2, John M H de Klerk3, Haiko J Bloemendal4,5, Daniela E Oprea-Lager6, Otto S Hoekstra6, H Pieter van den Berg7, Maartje Los8, Aart Beeker9, Marianne A Jonker10, Joe M O'Sullivan11, Henk M W Verheul12, Alfons J M van den Eertwegh12. 1. Department of Medical Oncology, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. jm.van.dodewaard@meandermc.nl. 2. Department of Medical Oncology, Meander Medical Centre, Maatweg 3, 3813 TZ, Amersfoort, The Netherlands. jm.van.dodewaard@meandermc.nl. 3. Department of Nuclear Medicine, Meander Medical Centre, Maatweg 3, 3813 TZ, Amersfoort, The Netherlands. 4. Department of Medical Oncology, Meander Medical Centre, Maatweg 3, 3813 TZ, Amersfoort, The Netherlands. 5. Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. 6. Department of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. 7. Department of Medical Oncology, Tergooi Medical Hospital, Van Riebeeckweg 212, 1213 XZ, Hilversum, The Netherlands. 8. Department of Medical Oncology, St Antonius Hospital Utrecht, Soestwetering 1, 3543 AZ, Utrecht, The Netherlands. 9. Department of Medical Oncology, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, The Netherlands. 10. Department of Epidemiology and Biostatistics, VU University Medical Centre, De Boelelaan 1089a, 1081 HV, Amsterdam, The Netherlands. 11. Centre for Cancer Research and Cell Biology, Queen's University Belfast, Lisburn Road, Belfast, BT9 7AB, Northern Ireland, UK. 12. Department of Medical Oncology, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Abstract
BACKGROUND:Rhenium-188-HEDP is a beta-emitting radiopharmaceutical used for palliation of metastatic bone pain. We investigated whether the addition of rhenium-188-HEDP to docetaxel/prednisone improved efficacy of chemotherapy in patients with CRPC. METHODS:Patients with progressive CRPC and osteoblastic bone metastases were randomised for first-line docetaxel 75 mg/m2 3-weekly plus prednisone with or without 2 injections of rhenium-188-HEDP after the third (40 MBq/kg) and after the sixth (20 MBq/kg) cycle of docetaxel. Primary endpoint was progression-free survival (PFS), defined as either PSA, radiographic or clinical progression. Patients were stratified by extent of bone metastases and hospital. RESULTS: Forty-two patients were randomised for standard treatment and 46 patients for combination therapy. Median number of cycles of docetaxel was 9 in the control group and 8 in the experimental group. Median follow-up was 18.4 months. Two patients from the experimental group did not start treatment after randomisation. In the intention to treat analysis no differences in PFS, survival and PSA became apparent between the two groups. In an exploratory per-protocol analysis median overall survival was significantly longer in the experimental group (33.8 months (95%CI 31.75-35.85)) than in the control group (21.0 months (95%CI 13.61-28.39); p 0.012). Also median PFS in patients with a baseline phosphatase >220U/L was significantly better with combination treatment (9.0 months (95%CI 3.92-14.08) versus 6.2 months (95%CI 3.08-9.32); log rank p 0.005). As expected, thrombocytopenia (grade I/II) was reported more frequently in the experimental group (25% versus 0%). CONCLUSION: Combined treatment with rhenium-188-HEDP and docetaxel did not prolong PFS in patients with CRPC. The observed survival benefit in the per-protocol analysis warrants further studies in the combined treatment of chemotherapy and radiopharmaceuticals.
RCT Entities:
BACKGROUND:Rhenium-188-HEDP is a beta-emitting radiopharmaceutical used for palliation of metastatic bone pain. We investigated whether the addition of rhenium-188-HEDP to docetaxel/prednisone improved efficacy of chemotherapy in patients with CRPC. METHODS:Patients with progressive CRPC and osteoblastic bone metastases were randomised for first-line docetaxel 75 mg/m2 3-weekly plus prednisone with or without 2 injections of rhenium-188-HEDP after the third (40 MBq/kg) and after the sixth (20 MBq/kg) cycle of docetaxel. Primary endpoint was progression-free survival (PFS), defined as either PSA, radiographic or clinical progression. Patients were stratified by extent of bone metastases and hospital. RESULTS: Forty-two patients were randomised for standard treatment and 46 patients for combination therapy. Median number of cycles of docetaxel was 9 in the control group and 8 in the experimental group. Median follow-up was 18.4 months. Two patients from the experimental group did not start treatment after randomisation. In the intention to treat analysis no differences in PFS, survival and PSA became apparent between the two groups. In an exploratory per-protocol analysis median overall survival was significantly longer in the experimental group (33.8 months (95%CI 31.75-35.85)) than in the control group (21.0 months (95%CI 13.61-28.39); p 0.012). Also median PFS in patients with a baseline phosphatase >220U/L was significantly better with combination treatment (9.0 months (95%CI 3.92-14.08) versus 6.2 months (95%CI 3.08-9.32); log rank p 0.005). As expected, thrombocytopenia (grade I/II) was reported more frequently in the experimental group (25% versus 0%). CONCLUSION: Combined treatment with rhenium-188-HEDP and docetaxel did not prolong PFS in patients with CRPC. The observed survival benefit in the per-protocol analysis warrants further studies in the combined treatment of chemotherapy and radiopharmaceuticals.
Entities:
Keywords:
Bone metastases; Chemotherapy; Docetaxel; Prostate cancer; Radiopharmaceutical; Rhenium-188-HEDP
Authors: David I Quinn; Catherine M Tangen; Maha Hussain; Primo N Lara; Amir Goldkorn; Carol M Moinpour; Mark G Garzotto; Philip C Mack; Michael A Carducci; J Paul Monk; Przemyslaw W Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Celestia S Higano; Nicholas J Vogelzang; Ian M Thompson Journal: Lancet Oncol Date: 2013-07-17 Impact factor: 41.316
Authors: Gerhardt Attard; Chris Parker; Ros A Eeles; Fritz Schröder; Scott A Tomlins; Ian Tannock; Charles G Drake; Johann S de Bono Journal: Lancet Date: 2015-06-11 Impact factor: 79.321
Authors: S M Tu; R E Millikan; B Mengistu; E S Delpassand; R J Amato; L C Pagliaro; D Daliani; C N Papandreou; T L Smith; J Kim; D A Podoloff; C J Logothetis Journal: Lancet Date: 2001-02-03 Impact factor: 79.321
Authors: H J Meulenbeld; E D van Werkhoven; J L L M Coenen; G J Creemers; O J L Loosveld; P C de Jong; A J Ten Tije; S D Fosså; M Polee; W Gerritsen; O Dalesio; R de Wit Journal: Eur J Cancer Date: 2012-06-06 Impact factor: 9.162
Authors: Holger Palmedo; Agnieska Manka-Waluch; Peter Albers; Ingo G H Schmidt-Wolf; Michael Reinhardt; Samer Ezziddin; Alexius Joe; Roland Roedel; Rolf Fimmers; F F Knapp; Stefan Guhlke; Hans-Jurgen Biersack Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: G D'angelo; R Sciuto; M Salvatori; I Sperduti; G Mantini; C L Maini; G Mariani Journal: Q J Nucl Med Mol Imaging Date: 2012-12 Impact factor: 2.346
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Karim Fizazi; Karim S Fizazi; Celestia S Higano; Joel B Nelson; Martin Gleave; Kurt Miller; Thomas Morris; Faith E Nathan; Stuart McIntosh; Kristine Pemberton; Judd W Moul Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544
Authors: Sungmin Woo; Chong Hyun Suh; Andreas G Wibmer; Anton S Becker; Min Yuen Teo; Mithat Gönen; Hedvig Hricak; Howard I Scher; Michael J Morris; Hebert Alberto Vargas Journal: Clin Genitourin Cancer Date: 2021-11-15 Impact factor: 2.872